• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Second Sight beat The Street in Q2 despite $8.44m loss

Second Sight beat The Street in Q2 despite $8.44m loss

August 7, 2019 By Nancy Crotti

Second Sight MedicalSecond Sight Medical (NSDQ:EYES) posted second-quarter results yesterday that beat both the sales and earnings forecasts on Wall Street as it accelerated its pivot toward manufacturing a new cortical implant.

Citing the costs of reorganization, the Sylmar, Calif.-based company reported a  loss of $8.44 million, or -0.07¢ per share, on sales of $1.28 million for the three months ended June 30, 2019, for a bottom-line loss of 6% on sales that dipped by 32.8% compared with Q2 2018. 

Adjusted to exclude one-time items, earnings per share were -$0.6, 1¢ ahead of The Street, where an analyst was looking for sales of $340,000.

The company announced in May that it would stop making its Argus 2 retinal implant in favor of focusing on the Orion cortical implant. It listed an impairment charge of $2.4 million in March based on Argus 2 inventory and its plans to suspend the device’s production. Second Sight reported restructuring charges of $873,000 in Q2 2019, which partially offset lower operating expenses.

In April, the company announced preliminary results from a small feasibility study of Orion, which is designed to give eyesight to the blind.

“We continue to make excellent progress with the development of the Orion platform and are working closely with the FDA to define pivotal study and post-market requirements,” Second Sight president & CEO Will McGuire said in a news release. “We commend CMS for creating a streamlined reimbursement pathway for innovative devices such as Orion with an FDA breakthrough devices designation. In preparation for Orion’s potential commercial launch, we are beginning to engage CMS and private payors in order to define the appropriate reimbursement pathways.

“Second Sight continues to pioneer the development of neuromodulation technology for artificial vision,” McGuire added. “The interim data from our Orion visual cortical prosthesis early feasibility study compare favorably to Argus and further support our belief in Orion’s potential to treat nearly all forms of blindness.”

For the second half of 2019, the company set goals of submitting Argus 2s to the FDA for approval, hire more staff to work on Orion and develop a plan for high-volume manufacturing.

Investors reacted by sending EYES shares down 3% to $0.76 at the close on Tuesday, but the stock had recovered to $0.79 at this afternoon’s close.

Filed Under: Blog, Business/Financial News, Featured, Neuromodulation/Neurostimulation, News Well, Prosthetics, Research & Development, Vision, Wall Street Beat Tagged With: Second Sight

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy